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What you need to know
• An adrenal incidentaloma is an adrenal lesion
found incidentally in asymptomatic patients
undergoing imaging scans not performed for
suspected adrenal disease. Adrenal
incidentalomas are becoming more common
due to increased scanning, as well as an older
population
• Most incidentalomas are benign and
non-functioning (~85%) and require only
minimal evaluation (but are frequently over
investigated). The remaining 15% (functioning
and/or malignant lesions) are at risk of under
investigation, delay, or even being missed
• Patients with adrenal incidentalomas can
experience anxiety once an adrenal
incidentaloma is detected and while awaiting
investigations or appointments
Sources and selection criteria
References were selected from Medline search,
focusing on published guidelines. Sub-references
were selected to ensure full coverage of the areas
identified within the initial search.
An incidental adrenal tumour, described in this article as an
“adrenal incidentaloma,” is an adrenal mass discovered during
imaging that was not performed for suspected adrenal disease.
These are being detected more frequently in an ageing
population1 through the increased use of computed tomography
(eg, computed tomography urogram, or colonoscopy) and
magnetic resonance imaging (MRI) scans with enhanced
resolution.2
This article highlights the management of adrenal
incidentalomas, collating recommendations from international
guidelines, and is aimed at non-specialists.
What is an adrenal incidentaloma?
Adrenal incidentalomas are defined as adrenal masses
incidentally discovered during imaging that was not performed
for suspected adrenal disease. Hence, an adrenal lesion
discovered while investigating raised catecholamines would not
be classified as an adrenal incidentaloma. Most definitions have
restricted the diagnosis to lesions ≥10 mm3 4 unless there are
clinical stigmas of adrenal hormone over-production identified
after the detection of the lesion that warrant further investigation.
In view of variation in diagnostic criteria, referral patterns, and
surgical rates, it is challenging to precisely classify the
underlying adrenal incidentaloma pathology from published
literature.2⇓ provides a simplified description of the adrenal
gland components, their role, and the consequences of excess
hormone production.
Who gets it?
Prevalence is estimated between ~2% (range 1.0%-8.7%) from
autopsy studies3-6 and ~4% in radiological studies, rising to 10%
in elderly patients.6-8 Prevalence is higher in patients with
diabetes, hypertension, or obesity.6 Adrenal incidentalomas are
rare in children (<0.04% of tumours).9
Most adrenal incidentalomas (~85%) are benign, with no
hormonal over-production (⇓).1-10 The remaining ~15%, however,
are either malignant or associated with hormone over-production
(excess cortisol, aldosterone, or catecholamine) and higher
morbidity-mortality, thereby requiring rigorous investigation.
The commonest functional abnormality for adrenal
incidentalomas is cortisol hyper-secretion, with
pheochromocytoma and hyper-aldosteronism being much less
common. A 50 year autopsy review of more than 40 000 cases
revealed pheochromocytomas in 0.13%, 76% of which were
only identified after death.11 Regardless of whether
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pheochromocytoma had been diagnosed or not, a common cause
of death was the development of hypertensive/hypotensive crisis,
often precipitated by unrelated surgery.
How are adrenal incidentalomas
managed?
The most recent recommendations from the European Society
of Endocrinology (2016)4 on managing adrenal incidentalomas
are summarised in ⇓. Comparisons with guidance from the
American Association of Clinical Endocrinologists (2009),12
Italian Association of Clinical Endocrinologists (2011),2 and
Canadian Urological Association (2011),13 is available in
supplementary table 1. These recommendations are mostly
derived from retrospective studies, case series, and consensus
opinion, and they largely agree that
• Screening is necessary for cortisol, aldosterone, and
catecholamines hyper-secretion; sex hormones are not routinely
measured unless clinically indicated
• Lipid-rich lesions are benign and require no further action
• Indeterminate or lipid-poor lesions require more detailed
attention.
Decision making approach
Is the lesion high risk?
When assessing patients with newly identified adrenal
incidentalomas to determine treatment options and prioritisation,
it is important to consider the risk of malignancy, and whether
the lesion is hyper-functioning (ie, secreting excessive amounts
of adrenal hormones). The risk of malignancy is small in patients
not previously known to have cancer. Two large retrospective
cohort studies have shown the risk of primary adrenocortical
carcinoma to be 4.7% and 5%, and that of metastasis 0.7% and
2.5%.1 14 In a pooled analysis from 26 international studies, the
prevalence of adrenocortical carcinomas was <5%.7 There is a
good correlation between risk and tumour size: 2% in lesions
≤4 cm, 6% in lesions 4.1–6 cm and 25% in lesions >6 cm.15
What is the risk of malignant transformation?
Size of lesion and its growth over time are key surrogates for
malignancy. Of those, size is the most reliable, with >40 mm
having the highest sensitivity (93%).14 It is unclear what would
qualify as a worrying rate of growth, especially as benign
adenomas also grow over time.2 Retrospective data10 showed
that, regardless of hormone over-secretion, benign adrenal
incidentalomas grew by 10-20 mm over three years.
If it is not making excess hormones now, could
that change in the future?
Given the limited prospective data, it is not possible to
conclusively document the progression towards hyper-secretion.
A literature review of longer term follow-up studies (>1 year),7
showed that, of 1147 patients with originally non-functional
adrenal incidentalomas, 20 (1.7%) developed hyper-function.
The most common evolution is cortisol over-production leading
to subclinical hyper-cortisolism.10 In a longitudinal follow-up
study of 284 consecutive patients with non-secreting adrenal
incidentalomas, the cumulative risk of developing subclinical
hyper-function was 6.6% after five years. Those >30 mm at
diagnosis were associated with a higher risk of hyper-function.16
Relative to excess cortisol production, future development of
excess aldosterone or catecholamines is unlikely (<0.1%).7
How might patients with malignant tumours
present?
Most adrenocortical carcinomas are discovered on incidental
imaging, and these patients are asymptomatic from an adrenal
viewpoint. Malignant adrenal tumours can be functional, and
patients might therefore display previously unrecognised features
of the corresponding hormone excess, mostly hypercortisolism
and/or virilisation. Patients rarely present with signs of
feminisation. The sudden onset of virilising clinical features,
gynaecomastia, or Cushing’s syndrome, might, respectively,
point towards an androgen, oestrogen, or cortisol producing
adrenocortical carcinoma.17 Some patients with adrenocortical
carcinomas might present with abdominal or flank pain,
abdominal fullness, and occasionally with constitutional
symptoms (eg, lethargy, fever, weight loss) secondary to
haemorrhage within the tumour.
Investigations to rule out malignancy
Guidelines agree that no further imaging is necessary where
initial scans indicate lipid-rich lesions of less than 10 Hounsfield
units (HU) (the measure of tissue density) in patients presenting
with no known malignancy; these are classified as benign
adenomas.4 Unfortunately, about one third of lesions will be
lipid-poor (>10 HU) and therefore it is difficult to exclude
malignancy. In these cases, a contrast enhanced triphasic adrenal
computed tomography scan should be undertaken, with the
calculation of the absolute and relative washout percentages.
An absolute washout >60% or relative washout >40% suggest
a benign lesion with excellent sensitivity (88%-96%) and
specificity (96%-100%).18⇓ shows computed tomography
examples of (a) lipid-rich and (b) lipid-poor lesions.
MRI is similarly effective, with the advantage of no radiation
exposure and avoiding the use of iodine based contrast agents.19
MRI is a safer option for younger patients and if repeated
imaging is required (eg, adrenal incidentalomas confirmed to
be pheochromocytomas with underlying genetic mutations;
these constitute 15%-20% of all catecholamine-secreting
tumours).
2-Deoxy-2-[fluorine-18] fluoro-D-glucose positron emission
tomography/computed tomography (18F-FDG PET/CT), a
technique that combines nuclear medicine with cross sectional
imaging,20 is particularly useful in detecting metastatic disease
in patients with primary adrenal cancer or secondaries from
other extra-adrenal malignancies.21 22 The newest imaging option
is 68Ga-dotatate PET, which has a higher specificity for
pheochromocytoma compared with FDG PET/CT.23
A recent meta-analysis of 32 observational studies including
2174 patients concluded that adrenal biopsy is useful in the
diagnosis of adrenal metastasis in patients with known
extra-adrenal malignancy. The authors concluded that adrenal
biopsy should only be performed if the findings would alter
patient management and after biochemical exclusion of a
phaeochromocytoma.24
There are no well established sensitive biochemical markers for
the diagnosis of adrenocortical carcinoma, or indeed adrenal
metastasis. A study including 45 individuals with adrenocortical
carcinomas and 102 patients with adrenocortical adenomas
showed that detailed serum and 24 hour urinary steroid profiling
had a sensitivity and specificity of 90% in differentiating benign
adrenal adenomas from adrenocortical carcinomas. Further work
is required to clarify whether such profiling could be useful for
monitoring.25
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Hormone over-production in adrenal
incidentaloma
Previously unrecognised clinical features of Cushing’s
syndrome, pheochromocytoma, or hyper-aldosteronism are
suggestive of functional lesions. In reality, however, most
adrenal incidentalomas are identified in patients who are
asymptomatic from an adrenal viewpoint.
All guidelines agree that hormonal evaluation by specialists is
crucial in all adrenal incidentalomas to exclude the three major
conditions associated with functional adrenal incidentaloma:
Glucocorticoid excess—There is consensus that the 1 mg
overnight dexamethasone suppression test should be the
initial screening test. Values <50 nmol/L (1.8 µg/dL) are
normal, while those >138 nmol/L (5 µg/dL) indicate
autonomous cortisol production (defined as subclinical
Cushing’s in the absence of clinical features). However, there
is lack of agreement on the interpretation of values between
50 nmol/L and 138 nmol/L in asymptomatic patients.
European guidelines define this as “possible autonomous
cortisol secretion,” and US, Italian, and Canadian guidelines
acknowledge its significance, despite the absence of
unequivocal data on the long term consequences. Another
potentially useful test for autonomous cortisol secretion is
serum dehydroepiandrosterone sulphate, which is reduced
in cortisol hyper-secretion because of adrenocorticotrophic
hormone suppression. The dehydroepiandrosterone sulphate
ratio (measured as dehydroepiandrosterone sulphate divided
by the lower reference limit) has been shown to have good
sensitivity and specificity in identifying adenomas with
autonomous cortisol secretion.26
Mineralocorticoid excess—The guidelines agree about
screening using plasma aldosterone (ng/dL)/renin (ng/mL/h)
ratio only in the presence of hypertension or unexplained
hypokalaemia. Values >20 (US guidelines) and >30–50
(Italian guidelines) require further confirmatory tests. The
sample should be taken in the morning, two hours after
getting out of bed, and after 5-15 minutes’ rest. A careful
assessment of the patient’s antihypertensive medication
should be undertaken (to evaluate potential impact on the
ratio) and some might need to be stopped before the test.27
Poor adherence to sampling criteria often leads to challenges
in interpretation.27
Catecholamine excess—All guidelines highlight the
importance of screening for pheochromocytoma with plasma
or urinary metanephrines, whether or not the patient is
hypertensive, as some patients with pheochromocytomas are
asymptomatic. Excluding a functioning pheochromocytoma
is crucial, as surgery without adequate α then β blockade
might be seriously detrimental to the patient.28 A value
greater than threefold above the upper reference range limit
confirms the diagnosis. Lower values might indicate a false
positive test, but pheochromocytoma should be considered
in patients with borderline values and indeterminate
computed tomography imaging features.4
In addition to the above investigations, patients with clinical
features of virilisation or gynaecomastia also need assessment
of androgen profile and oestrogen levels, respectively.13
Steroid precursors and urinary steroid profiles have also been
suggested, though these tests are labour intensive, expensive,
and not widely available. Evidence for their use in the diagnosis
of adrenocortical carcinoma is limited.
Some tumours secrete more than one hormone. Patients with
lesions causing both primary hyper-aldosteronism and
autonomous cortisol production have been reported.29 30
Follow-up
Follow-up of adrenal incidentalomas is dependent on the
characteristics of the original lesion. Current guidelines agree
that patients with benign lesions that are non-functional require
no further follow-up.4 Supplementary table 2 outlines variations
on this. However, prospective research studies should be
undertaken, as these will strengthen (or challenge) these
recommendations.
Present challenges and future direction
Despite current guidance, there remain two major challenges:
• Most patients with adrenal incidentalomas are not referred to
relevant specialists (endocrinologists/diabetologists), so there
is potential to miss functional or malignant lesions. That said,
investigating every lesion could overload any health system.
Therefore, an evidence based, streamlined approach is required
to ensure clinically effective and prompt evaluation, while
avoiding unnecessary investigations and clinic appointments.
We are developing an electronic adrenal incidentaloma
management system linked to the latest guidance.4 This will
provide more streamlined and timely management by bringing
all the key information together electronically and guiding the
management process, shortening the hands-on time for
healthcare professionals. This increased efficiency will facilitate
the management of all adrenal incidentaloma cases, including
those currently missed thereby enhancing patient safety.
• It is important to recognise that detection of adrenal
incidentaloma is associated with substantial patient anxiety
(unexpected nature, lack of standardised management pathway,
often poor communication from non-specialists); delay in
decision making should be avoided (see Tips for the
non-specialist).
Future developments in imaging and biochemical marker (eg,
steroid metabolites) assays might help differentiate benign from
malignant lesions and avoid unnecessary surgery.
How patients were involved in the creation of this
article
A patient with an adrenal incidentaloma provided A
patient’s perspective on their experience with
diagnosis and treatment. Our innovation project work
(funded by the Health Foundation) included focus
group discussion with patients, which highlighted
patient experience (anxiety given the unexpected
nature of the finding, the need for clear information
on what adrenal incidentaloma is, and the optimum
timelines for interaction with healthcare
professionals) and helped shape the article, in
particular the section on what to tell the patient (see
box Tips for the non-specialist).
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A patient’s perspective
Diagnosis
“Before diagnosis, I suffered sudden fluctuations in
body temperature and palpitations. My doctor sent
me for blood tests, which were all normal, and an
ultrasound scan. I was informed that the scan
showed they had found a lump and I was being
referred to a consultant.
“Once under hospital care, I felt totally swept along
with different scans and tests. I was informed that I
had an uncommon adrenal lump that can be serious.
The experience was overwhelming; I took in very
little information. I did my own research, but found
the internet confusing.”
Removal and beyond
“Blood pressure tablets were introduced in the weeks
before the surgery. While encouraging talks kept us
going; with hindsight, I realise that the operation was
risky. I was lucky to have a good outcome, going
home one week after surgery. I feel 100% better and
no longer get palpitations or temperature fluctuations.
“Family members were tested and none was found
to be carrying the broken gene; a relief to everyone.
“My care during and after diagnosis was excellent.
My advice to other patients is to trust the healthcare
professionals, feel free to ask questions, and ensure
internet information is from credible websites.”
Tips for the non-specialist
What to say to patients
• The scan that we arranged for you showed a
swelling on the adrenal gland. The adrenal
gland is a small but important gland that sits
on top of the kidney. It secretes a group of
hormones that are important for our wellbeing
• We are increasingly detecting these swellings
because our scanners are becoming better
• We know that these swellings could have been
present for many years. They are likely to stay
largely unchanged with no harm to you. We
are reassured by small swellings (<4 cm).
However, we still need to do some blood
tests/investigations to make sure all is well
• We will therefore refer you to an
endocrinologist/diabetologist (hormone
specialist) to do some tests. They will discuss
the results and scans in a meeting with other
specialists, such as endocrinologists,
radiologists, surgeons, and clinical biochemists
When to reassure patients
Patients will be anxious while awaiting the conclusion
of the investigations required by the hormone
specialist. Hence, any investigations need to be
timely. Lipid-rich swelling less than 4 cm in diameter
with no evidence of hormone over-production will
require no further intervention, and patients should
be reassured as soon as the biochemical results are
available4
When to refer to the endocrinology team4
• Refer all detected adrenal incidentalomas
• Where there is evidence of excess aldosterone
or cortisol, refer within 6-8 weeks
• Where there are large (or increasing in
size)/lipid-poor lesions (suspected malignancy)
or evidence of excess catecholamines, refer
within two weeks
Monitoring and prognosis
Lipid-rich swelling less than 4 cm in diameter with
no evidence of hormone over-production requires
no further action. Other lesions require specialist
input
Education into practice
• Can you measure the time from adrenal
incidentaloma detection to decision?
• How would you measure the effectiveness
and efficiency of your current process? How
could that be improved?
• Are there any cases that are currently
missed/inadequately followed up?
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Tables
Table 1| Percentage of the various subtypes of adrenal incidentalomas, based on pooled data from several series12710
Percentage of adrenal incidentalomasSubtypeType
71.2–82.4Apparent non-functioning adenomaNon-functional
5.3–7.9Subclinical (autonomous cortisol secretion) Cushing’s syndromeFunctional (hormonally active)
5.1–5.6Pheochromocytoma
1.0–1.2Aldosterone producing adenoma
4.4–4.7Adrenocortical cancerMalignant
2.1–2.5Metastatic cancer
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Table 2| Summary of key recommendations from recent European guidance on managing patients with a finding of an incidental adrenal
tumour
European guidance (2016)4Criterion
Recommendations for discussion of adrenal incidentalomas in MDT (any of the following):
      Imaging not consistent with a benign lesion
      Evidence of hormone excess (including autonomous cortisol secretion)
      Evidence of substantial tumour growth during follow-up imaging (more than 20%, or at least a 5 mm
increase in maximum diameter during the following 6-12 months)
      Adrenal surgery could be a consideration.
      Non-contrast computed tomography with determination of mass density to assess for malignancy.
One mg ODST and plasma/urinary metanephrines in all patients. ARR in all patients with concomitant
General recommendations
hypertension and/or unexplained hypokalaemia. Sex hormones and steroid precursors in patients with
clinical or imaging features of ACC
Clinical and biochemical assessment for cortisol production and co-morbidities. If worsening then consider
surgery
Surgical recommendation for subclinical Cushing
syndrome
            Unilateral adrenal tumour with clinically significant hormone excess
            Suspicion of malignancy
Indications for consideration for surgical intervention
1 mg ODSTSpecialist screening test for autonomous cortisol
production/subclinical Cushing’s syndrome
Following 1 mg ODST:
If cortisol between 51 and 138 nmol/L: “possible autonomous cortisol secretion.”
If cortisol >138 nmol/L (and without clinical features of Cushing’s): “autonomous cortisol secretion”
Diagnostic cut-off values for subclinical Cushing’s
syndrome
Plasma free or urinary fractionated metanephrinesSpecialist screening test for pheochromocytoma
ARRSpecialist screening test for hyperaldosteronism
In patients with clinical or radiological features of ACC (+steroid precursors)Specialist screening test for excess sex hormones
      In the setting of a newly diagnosed adrenal mass and a history of extra-adrenal malignancy:
      Lesion hormonally inactive
      Lesion has not been conclusively characterised as benign by imaging
      Management would be altered by the knowledge of histology
Indications for computed tomography guided needle
biopsy
Non-contrast computed tomography scan to determine whether the mass is homogenous and lipid rich
(<10 HU).
If indeterminate on non-contrast computed tomography, imaging with another modality (contrast computed
tomography, MRI, or FDG-PET)
Imaging
No further imaging if lesion <4 cm and clear benign features on imaging studies. Indeterminate mass
repeat non-contrast computed tomography or MRI after 6-12 months. Resect if growth by >20% in addition
to at least a 5 mm increase in max diameter. If growth below this threshold additional imaging after 6-12
months. No further hormonal investigation if initial evaluation normal unless new clinical signs of endocrine
activity or there is worsening of comorbidities—eg, hypertension or diabetes
Follow-up if not resected
MDT: multidisciplinary team, ODST: overnight dexamethasone suppression test, ARR: plasma aldosterone (ng/dL)/renin (ng/mL/h) ratio, ACC: adrenocortical
carcinoma, SCS: subclinical Cushing’s syndrome, HU: Hounsfield units, MRI: magnetic resonance imaging, FDG-PET: 2-deoxy-2-[fluorine-18]fluoro-D-glucose
positron emission tomography/computed tomography
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Figures
The components of the adrenal gland and consequences of excess hormone production
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Computed tomography showing lipid-rich and lipid-poor lesions. (a) A 2 cm left adrenal lesion showing a computed tomography
density of less than 10 HU, which is suggestive of a lipid-rich adenoma. (b) A 7.7 cm hypervascular left adrenal mass that
is suspicious for pheochromocytoma. Inset shows a metaiodobenzylguanidine scan demonstrating intense uptake in the
lesion
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